Shopping Cart
Remove All
Your shopping cart is currently empty
Lanadelumab (Synonyms: SHP-643, SHP643, DX-2930, DX2930)
Catalog No. T76710 Copy Product Info
Purity: 95%
🥰Excellent
Lanadelumab (SHP643) is a humanized IgG1 monoclonal antibody targeting plasma kallikrein (pKal) with a Ki value of 0.12 nM. Lanadelumab effectively inhibits both free pKal and its interaction with high molecular weight kininogen (HMWK)-bound pKal. Lanadelumab has demonstrated potential in hereditary angioedema research and represents a promising therapeutic antibody for studying kallikrein-kinin system regulation.
Lanadelumab
Copy Product Info🥰Excellent
Catalog No. T76710
Synonyms SHP-643, SHP643, DX-2930, DX2930
Lanadelumab (SHP643) is a humanized IgG1 monoclonal antibody targeting plasma kallikrein (pKal) with a Ki value of 0.12 nM. Lanadelumab effectively inhibits both free pKal and its interaction with high molecular weight kininogen (HMWK)-bound pKal. Lanadelumab has demonstrated potential in hereditary angioedema research and represents a promising therapeutic antibody for studying kallikrein-kinin system regulation.
Lanadelumab
Cas No. 1426055-14-2
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | - | In Stock | |
| 5 mg | $647 | - | In Stock | |
| 10 mg | $987 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.4% (SDS-PAGE); 99.2% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Lanadelumab (SHP643) is a humanized IgG1 monoclonal antibody targeting plasma kallikrein (pKal) with a Ki value of 0.12 nM. Lanadelumab effectively inhibits both free pKal and its interaction with high molecular weight kininogen (HMWK)-bound pKal. Lanadelumab has demonstrated potential in hereditary angioedema research and represents a promising therapeutic antibody for studying kallikrein-kinin system regulation. |
| Targets&IC50 | pKal:0.12 nM (Ki) |
| In vitro | Lanadelumab (0-1000 nM) inhibits the proteolytic activity of pKal toward its endogenous substrate, single-chain HMWK. Furthermore, in vitro studies demonstrate that Lanadelumab potently prevents HMWK proteolysis and the subsequent release of bradykinin, with an IC50 of 1.3 nM.[2] |
| In vivo | Lanadelumab (20 mg/kg; i.v. or s.c.) exhibits an extended half-life of approximately 12.5 days and effectively blocks high molecular weight kininogen proteolysis in activated plasma in a dose- and time-dependent manner in cynomolgus monkeys. Additionally, Lanadelumab (1, 30 mg/kg; s.c.) significantly inhibits carrageenan-induced paw edema in male Sprague-Dawley rats.[2] |
| Synonyms | SHP-643, SHP643, DX-2930, DX2930 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | KLKB1/Plasma Kallikrein |
| Molecular Weight | 145.70 kDa |
| Cas No. | 1426055-14-2 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Lanadelumab | purchase Lanadelumab | Lanadelumab cost | order Lanadelumab | Lanadelumab in vivo | Lanadelumab in vitro | Lanadelumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.